InChI=1S/C21H16F2N2O4/c1- 2- 21(28) 7- 18(26) 29- 9- 12- 13(21) 5- 17- 19- 11(8- 25(17) 20(12) 27) 3- 10- 4- 14(22) 15(23) 6- 16(10) 24- 19/h3- 6,28H,2,7- 9H2,1H3/t21- /m1/s1 |
LFQCJSBXBZRMTN-OAQYLSRUSA-N |
C12=CC(=C(C=C1N=C3C(=C2)CN4C(C5=C(C=C43)[C@](CC(OC5)=O)(CC)O)=O)F)F |
|
EC 5.99.1.2 (DNA topoisomerase) inhibitor
A topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA.
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
(5R)- 5- ethyl- 9,10- difluoro- 5- hydroxy- 1,4,5,13- tetrahydro- 3H,15H- oxepino[3',4':6,7]indolizino[1,2- b]quinoline- 3,15- dione
|
diflomotecan
|
WHO MedNet
|
diflomotécan
|
WHO MedNet
|
diflomotecán
|
WHO MedNet
|
diflomotecanum
|
WHO MedNet
|
(5R)- 5- ethyl- 9,10- difluoro- 1,4,5,13- tetrahydro- 5- hydroxy- 3H,15H- oxepino(3',4':6,7)indolizino(1,2- b)quinoline- 3,15- dione
|
ChemIDplus
|
BN 80915
|
ChEBI
|
BN-80915
|
ChEBI
|
BN80915
|
ChEBI
|
220997-97-7
|
CAS Registry Number
|
ChemIDplus
|
12482574
|
PubMed citation
|
Europe PMC
|
14519632
|
PubMed citation
|
Europe PMC
|
15011101
|
PubMed citation
|
Europe PMC
|
15229462
|
PubMed citation
|
Europe PMC
|
16261364
|
PubMed citation
|
Europe PMC
|
16995662
|
PubMed citation
|
Europe PMC
|
17322542
|
PubMed citation
|
Europe PMC
|
18654747
|
PubMed citation
|
Europe PMC
|
19053883
|
PubMed citation
|
Europe PMC
|
25948593
|
PubMed citation
|
Europe PMC
|
|